Evaluation of Acute Toxicity and Neuropharmacological Activities of PM-52

The neuropsychological disorders are increasing their importance nowadays. Unfortunately, the therapeutic efficacy is still not in satisfaction level. Therefore, the novel agents that are effective, safe, cheap and easy to approach are in required. Therefore, we aimed to determine the neuropharmacological activities of PM52, the novel herbal supplement. We had developed the PM52, a novel product comprising of Cissampelas pariera and Anethum graveolens at aconcentarion of 1: 5. Then, it was determined acute toxicity and the neuropharmacological activities of PM52. Male Wistar rats, weighing 180-220 g, were orally given PM52 up to the dose of 5000 mg.kg^-1 BW and observed acute toxicity. The neuropharmacological activities of PM52 were also determined. Various doses of PM52 ranging from 2, 10 and 50 mg.kg^-1 BW were orally given once daily to the animals at a period of 14 days. Anxiolytic, anti-depression and cognitive enhancing effects were evaluated after single administration and every 7 days throughout 14-day experimental period using elevated plus maze, forced swimming test and Morris water maze tests respectively. PM 52 was safe up to dose of 5000 mg kg^-1 BW. Moreover, it also showed anxiolytic-like activity and cognitive enhancing effect. Moreover, it also enhanced climbing activity in forced swimming test. PM 52 is the potential novel food supplement to enhance cognitive function and decrease anxiety. However, further researches on subchronic toxicity, possible active gradient and shelf life of product are also necessary before moving forward to clinical trial study.